載入...
Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma
Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and...
Na minha lista:
| Main Authors: | , , , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Dove Medical Press
2009
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2886329/ https://ncbi.nlm.nih.gov/pubmed/20616894 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|